邱录贵，1964年生，籍贯江西，永利集团3044官网欢迎您血液病医院主任医师，博士生导师，实验血液学国家重点实验室一级PI，天津市脐带血造血干细胞库医学主任。1985年毕业于江西医学院，1991年毕业于中国协和医科大学，取得医学硕士学位，同年就职于永利集团3044官网欢迎您血液病医院；1996-1999年应邀于美国路易斯维尔大学进行博士后研究工作；2000年晋升为主任医师。主要研究方向为淋系肿瘤基础与精准干预策略，是我国淋巴系统肿瘤领域的主要学科带头人之一。

主要研究方向为淋系肿瘤基础与精准干预策略。在多发性骨髓瘤、淋巴瘤、慢性淋巴细胞白血病以及成人急性淋巴细胞白血病的精确诊断和预后分层基础上的整体治疗方面积累了丰富的经验，在淋巴系统肿瘤的遗传学与分子发病机制研究方面取得系列重要成果。

1. Yi S#, Yan Y#, Jin M, Bhattacharya S, Wang Y, Wu Y, Yang L, Gine E, Clot G,Chen L, Yu Y, Zou D, Wang J, Phan AT, Cui R, Li F, Sun Q, Zhai Q, Wang T, Yu Z,Liu L, Liu W, Lyv R, Sui W, Huang W, Xiong W, Wang H, Li C, Xiao Z, Hao M, Wang J, Cheng T, Bea S, Herrera AF, Danilov A, Campo E, Ngo VN, Qiu L*, Wang L*. Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma. J Clin Invest. 2022 Feb 1;132(3):e153283.  (IF: 19.456)

2. Yu Z#, Wei X#, Liu L#, Sun H, Fang T, Wang L, Li Y, Sui W, Wang K, He Y, Zhao Y,Huang W, An G, Meng F, Huang C, Yu T, Anderson KC, Cheng T, Qiu L*, Hao M*.Indirubin-3'-monoxime acts as proteasome inhibitor: Therapeutic application in  multiple myeloma. E Bio Medicine. 2022 Apr;78:103950. (IF:11.205)

3. Gang An# , Daobin Zhou , Shu Cheng , Keshu Zhou , Jianyong Li , Jianfeng Zhou , Liping Xie, Jie Jin , Liye Zhong , Lingzhi Yan , Haiyi Guo , Chenmu Du , Jinhua Zhong , Yiling Yu , Binghao Wu , Lugui Qiu* . A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia. Clin Cancer Res. 2021 Oct 15;27(20):5492-5501. (IF: 12.531)

4. Di Wang# , Jue Wang# , Guang Hu , Wen Wang , Yi Xiao, Haodong Cai , Lijun Jiang , Li Meng , Yongkun Yang , Xiaoxi Zhou , Zhenya Hong , Zheng Yao , Min Xiao, Liting Chen, Xia  Mao , Li Zhu, Jin Wang, Lugui Qiu*, Chunrui Li*, Jianfeng Zhou*. A Phase I Study of a Novel Fully Human BCMA-Targeting CAR (CT103A) in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2021 May 27;137(21):2890-2901. (IF: 22.133)

5. Yi S#, Yan Y#, Jin M, Xiong W, Yu Z, Yu Y, Cui R, Wang J, Wang Y, Lin Y, Jia Y,Zhang D, Wang T, Lv R, Liu W, Sui W, Huang W, Fu M, Xu Y, Deng S, An G, Zou D,Li Z, Shi J, Xiao Z, Wang J, Cheng T, Gale RP, Wang L*, Qiu L*. High incidence ofMYD88 and KMT2D mutations in Chinese with chronic lymphocytic leukemia. Leukemia. 2021Aug;35(8):2412-2415. Jan 22. (IF:12.883)

6. Xu Y#, Fulciniti M*, Samur MK, Ho M, Deng S, Liu L, Wen K, Yu T, Chyra Z, Dereibal S, Zhang L, Yao Y, Chakraborty C, Morelli E, Li N, Lopez MA, Perini T, Mu S, An G, Alonso R,Bianchi G, Tai YT, Anderson KC, Qiu L*, Munshi NC*. YWHAE/14-3-3ε expression impacts the protein load contributing to proteasome inhibitor sensitivity in multiple myeloma. Blood. 2020，136(4):468-479. (IF:16.509)

7. An G#*, Yan Y#, Xu Y, Mao X, Liu J, Fan H,Wang Q, Du C, Li Z, Yi S, Lv R, Deng S, Sui W, Fu M, Hao M, Huang W, Zou D, Zhao Y, Yuan C, Du X, Wang J, Cheng T, Tai YT, Munshi NC*, Qiu  L*. Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma. Leukemia. 2020,34(2):578-588. (IF:11.528)

8. Franqui-Machin R#, Hao M#, Bai H, Gu Z,Zhan X, Habelhah H, Jethava Y, Qiu L*, Frech  I, Tricot G, Zhan F*. Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma. J Clin Invest. 2018,128(7):2877-2893. (IF:12.87)

9. Qin Y#, Zhang S#, Deng S#, An G, Qin X, Li F, Xu Y, Hao M, Yang Y, Zhou W*, Chang H*, Qiu L*.  Epigenetic silencing of miR-137 induces drug resistance and chromosomal instability by targeting AURKA in multiple myeloma. Leukemia. 2017.31(5):123-1135. (IF:11.412)

10. Yi S#, Li Z, Zou D, An G, Cui R, Zhong S, Li H, Xiong W, Li C, Chen W, Liu W, Lv R, Yu Z, Wang H, Xu Y, Zhou K, Ru K, Wang J, Cheng T, Qiu L*. Intratumoral genetic heterogeneity and number of cytogenetic aberrations provide additional prognostic significance in chronic lymphocytic leukemia. Genet Med.19(2):182-191. (IF:7.756)